HCPCS Level II code A9583 designates a 1 ml injection of gadofosveset trisodium, a gadolinium-based contrast agent used to enhance magnetic resonance imaging studies, particularly vascular and tissue characterization. The code is clinically significant for facilities and imaging providers because it specifies the administered contrast product and unit volume, which affects inventory tracking, billing line-itemization, and reimbursement processing at the national level.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of payment and coverage considerations across major commercial and federal payers, context on typical sites of service where this injectable agent is used, and operational implications for imaging departments. The publication outlines benchmarking elements relevant to charge capture and claim submission, notes any recent policy updates affecting contrast agent coding and coverage where available, and explains clinical circumstances that commonly prompt use of the agent.

This resource targets coding professionals, revenue cycle staff, and radiology administrators seeking a national-level reference for coding, billing, and administrative handling of HCPCS Level II code A9583. Data not available in the input will be identified explicitly in the appropriate sections.